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Microsatellite Instability Predicts Response to  
Anti-PD1 Immunotherapy in Metastatic Melanoma
Dear editor,
immune-checkpoint blockade is a type of pas-
sive immunotherapy aimed at enhancing preexisting 
anti-tumor responses of the organism, blocking self-
tolerance molecular interactions between t-lympho-
cytes and neoplastic cells (1,2). Despite a significant 
increase in progression-free survival, a large propor-
tion of patients affected by metastatic melanoma do 
not show durable responses even after appropriate 
diagnostic categorization and shared therapeutic 
choices (3-9). therefore, predictive biomarkers of 
clinical response are urgently needed, and predictive 
immunohistochemistry (ihC) meets these require-
ments. Strong evidence suggests that DNA mismatch 
repair (MMr) deficiency is a frequent condition in 
malignant melanoma, as well as in other tumors (10). 
As is known, DNA MMr is a safeguard system for the 
detection and repair of DNA errors, which can ran-
domly occur in the phase of DNA replication inside 
Figure 1. Subungual primary melanoma with metastatic spreading to the brain and ileum in a middle-aged female patient 
treated with significant benefit by pembrolizumab: when compared with Mlh1, Pms2 and Msh2 status, the exclusive loss of 
ihC expression for Msh6 protein has been established. the ileal metastasis, here illustrated, and the one in the brain show the 
same ihC profile of the primary melanoma; they are in fact characterized by an exclusive loss of ihC expression for Msh6 pro-
tein, if compared with Mlh1, Pms2, and Msh2 status (hematoxylin and eosin; Mlh1: clone M1, Ventana; Pms2: clone ePr3947, 
Ventana; Msh2: clone G219-1129, Ventana; Msh6: clone 44, Ventana; chromogen: 3,3’ diaminobenzidine tetrahydrochloride 
hydrate; original magnification: ×10).
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the cell. in humans, seven DNA MMr proteins (Mlh1, 
Mlh3, Msh2, Msh3, Msh6, Pms1, and Pms2) work in a 
coordinated and sequential manner to repair DNA 
mismatches. When this system is defective, the cell 
accumulates a series of replication errors in terms of 
new microsatellites; therefore, a condition of genetic 
hypermutability and microsatellite instability (MSi) 
takes place inside the cell itself (11). For this reason, 
my working group has started to search for MMr pro-
tein deficiency in melanoma biopsies from patients 
of both sexes and of all ages with metastatic spread, 
correlating the data with the response to pembroli-
zumab, the well-known anti-programmed cell death 
protein 1 (PD1) human monoclonal immunoglobulin 
G4, capable of blocking the interaction between PD1, 
the surface receptor of activated t-lymphocytes, and 
its ligand, the programmed death-ligand 1 (PD-L1), 
favoring melanoma cell attack by t-lymphocytes (1) 
rather than its depression (12). PD-L1 is highly ex-
pressed in about half of all melanomas and thus the 
role of PD1 in melanoma immune evasion is now well 
established (13). Surprisingly, the best therapeutic re-
sults to pembrolizumab, in terms of progression-free 
survival and overall survival, occur precisely in those 
patients, approximately 7% in my database, affected 
by deficient MMr (dMMr) melanomas. in particular, 
the most important benefits to pembrolizumab-
based treatment have occurred in a female patient, 
who developed a subungual melanoma in the second 
finger of the left hand at the age of 41 years, together 
with lymph node metastases to ipsilateral axilla at the 
onset. the patient was promptly submitted to ampu-
tation of the first phalanx and emptying of the axillary 
cable. the primary tumor was a vertical growth phase 
melanoma with a Breslow’s depth of 1.4 mm; three 
mitotic figures for 1 mm2 were ascertained. there was 
no evidence of ulceration, regression, microsatellit-
osis, or lymphocytic infiltration; moreover, the surgi-
cal margins tested free of disease. Further molecular 
analyses did not show rearrangements in B-rAF and 
C-Kit genes. After four years, metastases appeared in 
the brain and ileum; however, at present the patient 
is still alive and in complete pembrolizumab response 
with progression-free survival and overall survival of 
956 days and 2546 days, respectively. the tumor was 
afterwards identified as a dMMr melanoma for an ex-
clusive loss of Msh6 expression on ihC (Figure 1). this 
finding is in line with the fact that the U.S. Food and 
Drug Administration has approved the use of pem-
brolizumab in 2017 for unresectable or metastatic 
solid tumors with MMr deficiency (14). in conclusion, 
dMMr melanoma seems to be a particular subset of 
disease that can be identified with high sensibility 
and specificity by predictive ihC as a complete loss 
of one or more DNA MMr proteins and that deserves 
targeted therapy.
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